This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nettelbeck, D. M. Articles by Curiel, D. T. Search for Related Content PubMed PubMed Citation Articles by Nettelbeck, D. M. Articles by Curiel, D. T.

Novel Oncolytic Adenoviruses Targeted to Melanoma

Specific Viral Replication and Cytolysis by Expression of E1A Mutants from the Tyrosinase Enhancer/Promoter¹

Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-2172

Malignant melanoma is characterized by growing incidence, early metastasis, and a lack of effective treatment for advanced disease, suggesting a pressing need for novel therapeutic approaches. Conditionally replicative adenoviruses (CRAds) constitute a new and promising strategy for cancer treatment that has been rapidly translated into clinical trials. We engineered novel melanoma-targeted CRAds, AdTyr24 and AdTyr224, by replacing the adenoviral E1A promoter with a cassette containing a polyA sequence and a human tyrosinase enhancer/promoter construct (hTyr2E/P). The small size of this cassette allows retention of the E3 region within these CRAds, which was shown to enhance viral spread and oncolysis. In addition, we introduced mutations (24 and 224) into the viral E1A gene, which attenuate adenoviral replication in quiescent cells. The cell cycle pathways mediating this attenuation are defective in melanoma cells. By analysis of E1A expression, we prove fidelity of hTyr2E/P in the adenoviral genome and in the context of viral replication when an upstream polyA was included. We further show efficient cytotoxicity of AdTyr24 and AdTyr224 in melanoma cell lines and a 100-1000-fold attenuation in cell lines derived from various nonmelanocytic tissues. Virus replication and progeny production of these viruses were similarly selective, resulting in 200–800-fold higher virus yields in melanoma cells versus control cells, thus establishing viral cytolysis and spread as the cause of the observed cell killing. Cytotoxicity of AdTyr24 for normal fibroblasts and keratinocytes was strongly attenuated, and this virus caused selective killing of melanoma cells but not surrounding keratinocytes in a coculture system. Progeny production and cytotoxicity of AdTyr24 in melanoma cells were similar to matching viruses containing the stronger cytomegalovirus enhancer/promoter instead of hTyr2E/P. Furthermore, AdTyr24 showed a cytopathic effect similar to the wild-type E1A containing AdTyrwt and only minimally reduced compared with wild-type adenovirus. We conclude that the generated CRAds AdTyr24 and AdTyr224 constitute novel targeted agents for gene therapy and viral oncolysis of metastatic melanoma.

This article has been cited by other articles:

				C. M. Hine, A. Seluanov, and V. Gorbunova Use of the Rad51 promoter for targeted anti-cancer therapy PNAS, December 30, 2008; 105(52): 20810 - 20815. [Abstract] [Full Text] [PDF]

				G. J. Bauerschmitz, T. Ranki, L. Kangasniemi, C. Ribacka, M. Eriksson, M. Porten, I. Herrmann, A. Ristimaki, P. Virkkunen, M. Tarkkanen, et al. Tissue-Specific Promoters Active in CD44+CD24-/low Breast Cancer Cells Cancer Res., July 15, 2008; 68(14): 5533 - 5539. [Abstract] [Full Text] [PDF]

				Y. Tsuruta, L. Pereboeva, M. Breidenbach, D. T. Rein, M. Wang, R. D. Alvarez, G. P. Siegal, P. Dent, P. B. Fisher, and D. T. Curiel A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3582 - 3588. [Abstract] [Full Text] [PDF]

				J. Leja, H. Dzojic, E. Gustafson, K. Oberg, V. Giandomenico, and M. Essand A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2455 - 2462. [Abstract] [Full Text] [PDF]

				A. Hesse, D. Kosmides, R. E. Kontermann, and D. M. Nettelbeck Tropism Modification of Adenovirus Vectors by Peptide Ligand Insertion into Various Positions of the Adenovirus Serotype 41 Short-Fiber Knob Domain J. Virol., March 15, 2007; 81(6): 2688 - 2699. [Abstract] [Full Text] [PDF]

				J. Kamizono, S. Nagano, Y. Murofushi, S. Komiya, H. Fujiwara, T. Matsuishi, and K.-i. Kosai Survivin-Responsive Conditionally Replicating Adenovirus Exhibits Cancer-Specific and Efficient Viral Replication Cancer Res., June 15, 2005; 65(12): 5284 - 5291. [Abstract] [Full Text] [PDF]

				D. T. Rein, M. Breidenbach, T. O. Kirby, T. Han, G. P. Siegal, G. J. Bauerschmitz, M. Wang, D. M. Nettelbeck, Y. Tsuruta, M. Yamamoto, et al. A Fiber-Modified, Secretory Leukoprotease Inhibitor Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1327 - 1335. [Abstract] [Full Text] [PDF]

				R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]

				N. S. Banerjee, A. A. Rivera, M. Wang, L. T. Chow, T. R. Broker, D. T. Curiel, and D. M. Nettelbeck Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures Mol. Cancer Ther., April 1, 2004; 3(4): 437 - 449. [Abstract] [Full Text] [PDF]

				D. J. Waxman and P. S. Schwartz Harnessing Apoptosis for Improved Anticancer Gene Therapy Cancer Res., December 15, 2003; 63(24): 8563 - 8572. [Abstract] [Full Text] [PDF]